You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》君聖泰醫藥通過聯交所聆訊 海普瑞(09989.HK)持股24%
內地生物製藥公司君聖泰醫藥(HighTide Therapeutics)近日通過聯交所上市聆訊,由瑞銀、華泰國際任聯席保薦人。 聆訊後資訊顯示,君聖泰醫藥專注於就代謝及消化系統疾病的治療,發現、開發及商業化多功能及多靶點療法,目前擁有自主開發包含1款核心產品及4款其他候選產品的產品管線,涵蓋9種適應症,其中5種適應症處於臨床開發階段。 於上市前,大股東AIC集團持股30.84%,而天使投資人海普瑞(09989.HK)則持股24.06%。另外,廣源國際投資、泰格醫藥(03347.HK)、中信、中醫藥基金等亦為君聖泰醫藥的上市前投資者。 截至今年6月底止中期,公司錄得全面虧損約5.86億元人民幣,對比上年同期全面虧損約9,238.7萬元人民幣。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account